Healthcare firm Personalis' Q2 revenue misses estimates

Personalis

05/08/2025 21:12

Overview

Personalis Q2 2025 revenue drops 24%, missing analyst expectations, per LSEG data

Company reports 59% sequential growth in clinical test volume for Q2

Personalis expands Tempus AI partnership to include colorectal cancer

Outlook

Personalis expects Q3 revenue between $12.0 mln and $14.0 mln

Company sees full-year revenue at $70 mln to $80 mln

Personalis anticipates Q3 pharma tests revenue of $11.0 mln to $13.0 mln

Company expects full-year gross margin of 22% to 24%

Result Drivers

CLINICAL TEST VOLUME - 59% sequential growth in clinical test volume driven by physician adoption of NeXT Personal platform

PARTNERSHIP EXPANSION - Expanded collaboration with Tempus AI to include colorectal cancer, aiming to capture new market

CLINICAL EVIDENCE - Presented pivotal data at ASCO showing NeXT Personal's ability to predict therapy response in breast cancer

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Miss
$17.20 mln
$20.10 mln (7 Analysts)
Q2 EPS
-$0.23
Q2 Net Income
-$20.06 mln
Q2 Basic EPS
-$0.23
Q2 Income From Operations
-$21.80 mln
Q2 Pretax Profit
-$20.05 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Personalis Inc is $7.50, about 25.7% above its August 4 closing price of $5.57

Press Release: ID:nBw2Tp3Yxa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)